Sugi Predict

Sugi Predict / Targets / TESK2

TESK2

Dual specificity testis-specific protein kinase 2 · Q96S53 · TESK2 on Sugi Atlas →

312 patent compounds predicted against TESK2, 216 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL5999941 SCHEMBL5999941 1.00 6/20
SCHEMBL6000061 SCHEMBL6000061 1.00 6/20
SCHEMBL6001849 SCHEMBL6001849 1.00 6/20
SCHEMBL6002058 SCHEMBL6002058 1.00 6/20
SCHEMBL6002069 SCHEMBL6002069 1.00 6/20
SCHEMBL6002138 SCHEMBL6002138 1.00 6/20
SCHEMBL1616746 SCHEMBL1616746 0.86 6/20
SCHEMBL6001580 SCHEMBL6001580 0.86 6/20
SCHEMBL6001871 SCHEMBL6001871 0.85 6/20
SCHEMBL6001859 SCHEMBL6001859 0.84 6/20
SCHEMBL6001595 SCHEMBL6001595 0.84 6/20
SCHEMBL6001860 SCHEMBL6001860 0.83 6/20
SCHEMBL6002150 SCHEMBL6002150 0.83 6/20
SCHEMBL6001374 SCHEMBL6001374 0.82 6/20
SCHEMBL6001579 SCHEMBL6001579 0.82 6/20
SCHEMBL6001363 SCHEMBL6001363 0.82 6/20
SCHEMBL6001588 SCHEMBL6001588 0.82 6/20
SCHEMBL6001635 SCHEMBL6001635 0.82 6/20
SCHEMBL1616940 SCHEMBL1616940 0.82 6/20
SCHEMBL6001410 SCHEMBL6001410 0.81 6/20

Clinical trials — most relevant to TESK2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve) PHASE3WITHDRAWN
Impact of tdrd9 Gene Mutations in the Therapeutic Response to L-carnitine in Oligoasthenozoospermic Men PHASE3ACTIVE_NOT_RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer PHASE2COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Cause of Familial Testicular Cancer nanCOMPLETED
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders nanCOMPLETED
Azoospermia Patients nanRECRUITING
Study of Sperm Molecular Factors Implicated in Male Fertility nanCOMPLETED
Genetic Studies Spermatogenic Failure nanCOMPLETED
Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women nanCOMPLETED
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease nanRECRUITING
Patient's Derived Organoids for Drug Screening in Glioblastoma nanNOT_YET_RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study nanCOMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
COPENHAGEN Minipuberty Study nanUNKNOWN
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib nanCOMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
Seminal Levels of PGK2 and ACRV1 as Predictors of Micro-TESE Results in NOA nanUNKNOWN
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer nanUNKNOWN
Next-Generation Sequencing-based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer nanUNKNOWN
Impact of Weight Loss on the Human Sperm Epitranscriptome nanACTIVE_NOT_RECRUITING
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a TESK2 binder may also engage these)

ProteinNameSimilarity
Q924U5 — 1.000 Q924U5 →
Q8VCT9 — 1.000 Q8VCT9 →
Q60700 — 1.000 Q60700 →
Q3ULB5 — 0.997 Q3ULB5 →
Q6P0Q8 — 0.996 Q6P0Q8 →
Q63553 — 0.996 Q63553 →
Q66HE5 — 0.996 Q66HE5 →
MAP3K13 Mitogen-activated protein kinase kinase kinase 13 0.995 landscape →
Q8BWQ5 — 0.995 Q8BWQ5 →
Q5R8X7 — 0.995 Q5R8X7 →
Q641K5 — 0.994 Q641K5 →
Q68UT7 — 0.994 Q68UT7 →
Q76I79 — 0.994 Q76I79 →
Q5R8Z4 — 0.994 Q5R8Z4 →
MAP3K9 Mitogen-activated protein kinase kinase kinase 9 0.994 landscape →
A7MBB4 — 0.994 A7MBB4 →
Q8BZN4 — 0.994 Q8BZN4 →
Q63796 — 0.994 Q63796 →
Q2PFD7 — 0.993 Q2PFD7 →
Q80UE6 — 0.993 Q80UE6 →
F1MJR8 — 0.993 F1MJR8 →
Q8K330 — 0.993 Q8K330 →
NUAK1 NUAK family SNF1-like kinase 1 0.993 landscape →
Q9BQK8 — 0.993 Q9BQK8 →
MAP3K12 Mitogen-activated protein kinase kinase kinase 12 0.993 landscape →
D3ZML2 — 0.992 D3ZML2 →
Q3UIZ8 — 0.992 Q3UIZ8 →
O70405 — 0.992 O70405 →
Q8VDU5 — 0.992 Q8VDU5 →
Q811L6 — 0.992 Q811L6 →